497

Compound name
Deucravacitinib
Alt Name
BMS-986165
Tyk2-IN-4
Sotyktu
Compound Image
Deucravacitinib.png
SMILES
CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
MW
425.50
Brutto
C20H22N8O3
InChI
InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
InChI Key
BZZKEPGENYLQSC-FIBGUPNXSA-N
Approval Jurisdiction
2022 FDA
Approved for clinical use
Psoriasis
CAS
1609392-27-9
PubChem CID
134821691
Action
TYK2
Approved Drug List
1
Commercial Vendor
Bristol-Myers Squibb